Addition of sodium glucose cotransporter 2 (SGLT2) inhibitor to glucagon-like peptide-1 (GLP-1) receptor agonist therapy in obese people with Type 2 diabetes and suboptimal glycaemic control

被引：0
|
作者：
Curtis, L. R. [1 ]
Walker, J. I. [1 ]
Knott, J. [1 ]
Partridge, H. L. [1 ]
机构：
[1] Royal Bournemouth & Christchurch Hosp NHS Fdn Tru, Diabet & Endocrine Ctr, Bournemouth, Dorset, England
来源：
DIABETIC MEDICINE | 2016年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P529
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [11] Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor
    DeFronzo, Ralph A.
    DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1353 - 1362
  • [12] Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
    de Oliveira Costa, Juliana
    Lin, Jialing
    Milder, Tamara Y.
    Greenfield, Jerry R.
    Day, Richard O.
    Stocker, Sophie L.
    Neuen, Brendon L.
    Havard, Alys
    Pearson, Sallie-Anne
    Falster, Michael O.
    DIABETES OBESITY & METABOLISM, 2024, 26 (07): : 2787 - 2795
  • [13] A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus
    Thondam, S. K.
    Cuthbertson, D. J.
    Aditya, B. S.
    MacFarlane, I. A.
    Wilding, J. P.
    Daousi, C.
    CLINICAL ENDOCRINOLOGY, 2012, 77 (04) : 635 - 637
  • [14] How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? Completed and Ongoing Mechanistic Trials
    Lee, Matthew M. Y.
    Petrie, Mark C.
    McMurray, John J. V.
    Sattar, Naveed
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2020, 40 (03) : 506 - 522
  • [15] Glucagon-like peptide-1 (GLP-1) levels in obese patients with and without type 2 diabetes.
    Mannucci, E
    Ognibene, A
    Cremasco, F
    Bardini, G
    Mencucci, A
    Ciani, S
    Messeri, G
    Rotella, CM
    DIABETOLOGIA, 2000, 43 : A146 - A146
  • [16] Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes
    Goldenberg, Ronald M.
    Ahooja, Vineeta
    Clemens, Kristin K.
    Gilbert, Jeremy D.
    Poddar, Megha
    Verma, Subodh
    CANADIAN JOURNAL OF DIABETES, 2021, 45 (03) : 291 - 302
  • [17] Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD
    Gregg, L. Parker
    Richardson, Peter A.
    Nambi, Vijay
    Petersen, Laura A.
    Matheny, Michael E.
    Virani, Salim S.
    Navaneethan, Sankar D.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025, 36 (01): : 87 - 98
  • [18] An audit of glucagon-like peptide 1 (GLP-1) agonist use in obese people with Type 1 diabetes
    Singh, B. M.
    Dudley, J.
    Gillani, S. R.
    DIABETIC MEDICINE, 2013, 30 : 81 - 81
  • [19] Cardiovascular effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) in routine care of frail people with type 2 diabetes
    Kutz, Alexander
    Gopalakrishnan, Chandrasekar
    Kim, Dae Hyun
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 98 - 99
  • [20] Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes
    Ross, Stuart A.
    Ballantine, Jane
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (12) : 1617 - 1626
12345